Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears to think they’re manageable.
Category: Tylenol (Drug)
-
With Acquisition, Kimberly-Clark Bets That Tylenol Can Weather the Storm
The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven claims from President Trump and others that use of the pain reliever during pregnancy can cause autism.
-
With Acquisition, Kimberly-Clark Bets That Tylenol Can Weather the Storm
The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven claims from President Trump and others that use of the pain reliever during pregnancy can cause autism.
-
Kimberly-Clark to Buy Tylenol Maker Kenvue for $40 Billion
The owner of Kleenex and Huggies will acquire the company that has fought claims by the Trump administration that a common pain reliever is linked to harmful side effects.
-
Texas Sues Tylenol Makers, Claiming They Hid Autism Risks
The lawsuit follows claims by President Trump that linked use by pregnant women of acetaminophen to autism, a connection that is unproven.
-
Taking Too Much Tylenol Has Proven Risks. Trump Didn’t Talk About Those.
Acetaminophen’s link to autism is unproven. But hundreds of Americans accidentally overdose on the drug each year, suffering liver damage that can require a transplant or even be fatal.
-
The Company Behind Tylenol Tries to Navigate Its Latest Crisis
Kenvue, a two-year-old spinoff from Johnson & Johnson, is confronting a public-relations nightmare as President Trump and others suggest unproven links between the pain reliever and autism.